Diagnosis and treatment of cutaneous melanoma: State of the art 2006

Melanoma Research

Volumn 17, Issue 2, 2007, Pages 117-127

  Garbe, Claus ^a   Eigentler, Thomas K ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DACARBAZINE;

ALGORITHM; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER SURVIVAL; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DISEASE FREE INTERVAL; EARLY DIAGNOSIS; EPILUMINESCENCE MICROSCOPY; HUMAN; MELANOMA; MICROMETASTASIS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN CARCINOMA; SKIN METASTASIS; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; WHOLE BODY MRI;

ADULT; CHILD; CHILD, PRESCHOOL; HUMANS; INCIDENCE; MEDICAL ONCOLOGY; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; RISK FACTORS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 34247635551     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328042bb36     Document Type: Conference Paper

References (98)

1. Berwick M, Halpern A. Melanoma epidemiology. Curr Opin Oncol 1997; 9:178-182.
2. Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001; 14:280-290.
3. Geller AC, Miller DR, Annas GD, Demierre MF, Gilchrest BA, Koh HK. Melanoma incidence and mortality among US whites, 1969-1999. JAMA 2002; 288:1719-1720.
4. Hall HI, Miller DR, Rogers JD, Bewerse B. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol 1999; 40:35-42.
5. Carli P, Borgognoni L, Biggeri A, Carli S, Reali UM, Giannotti B. Incidence of cutaneous melanoma in the centre of Italy: anatomic site distribution, histologic types and thickness of tumour invasion in a registry-based study. Melanoma Res 1994; 4:385-390.
6. MacLennan R, Green AC, McLeod GR, Martin NG. Increasing incidence of cutaneous melanoma in Queensland, Australia. J Natl Cancer Inst 1992; 84:1427-1432.
7. Mansson-Brahme E, Johansson H, Larsson O, Rutqvist LE, Ringborg U. Trends in incidence of cutaneous malignant melanoma in a Swedish population 1976-1994. Acta Oncol 2002; 41:138-146.
8. de Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003; 107:119-126.
9. Bosetti C, La Vecchia C, Naldi L, Lucchini F, Negri E, Levi F. Mortality from cutaneous malignant melanoma in Europe. Has the epidemic levelled off? Melanoma Res 2004; 14:301-309.
10. Garbe C, McLeod GR, Buettner PG. Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer 2000; 89:1269-1278.
11. MacKie RM, Bray CA, Hole DJ, Morris A, Nicolson M, Evans A, et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002; 360:587-591.
12. Garbe C, Buttner P, Weiss J, Soyer HP, Stocker U, Kruger S, et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol 1994; 102:695-699.
13. Grob JJ, Gouvernet J, Aymar D, Mostaque A, Romano MH, Collet AM, et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 1990; 66:387-395.
14. Holly EA, Kelly JW, Shpall SN, Chiu SH. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 1987; 17:459-468.
15. Bauer J, Garbe C. Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res 2003; 16:297-306.
16. Harrison SL, MacKie RM, MacLennan R. Development of melanocytic nevi in the first three years of life. J Natl Cancer Inst 2000; 92:1436-1438.
17. Luther H, Altmeyer P, Garbe C, Ellwanger U, Jahn S, Hoffmann K, Segerling M. Increase of melanocytic nevus counts in children during 5 years of follow-up and analysis of associated factors. Arch Dermatol 1996; 132:1473-1478.
18. Wiecker TS, Luther H, Buettner P, Bauer J, Garbe C. Moderate sun exposure and nevus counts in parents are associated with development of melanocytic nevi in childhood: a risk factor study in 1,812 kindergarten children. Cancer 2003; 97:628-638.
19. Bauer J, Buttner P, Wiecker TS, Luther H, Garbe C. Risk factors of incident melanocytic nevi: a longitudinal study in a cohort of 1,232 young German children. Int J Cancer 2005; 115:121-126.
20. Bauer J, Buttner P, Wiecker TS, Luther H, Garbe C. Effect of sunscreen and clothing on the number of melanocytic nevi in 1,812 German children attending day care. Am J Epidemiol 2005; 161:620-627.
21. Bauer J, Buttner P, Wiecker TS, Luther H, Garbe C. Interventional study in 1,232 young German children to prevent the development of melanocytic nevi failed to change sun exposure and sun protective behavior. Int J Cancer 2005; 116:755-761.
22. Argenziano G, Soyer HP, Chimenti S, Talamini R, Corona R, Sera F, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the internet. J Am Acad Dermatol 2003; 48:679-693.
23. Pehamberger H, Steiner A, Wolff K. In vivo epiluminescence microscopy of pigmented skin lesions. I. Pattern analysis of pigmented skin lesions. J Am Acad Dermatol 1987; 17:571-583.
24. Pehamberger H, Binder M, Steiner A, Wolff K. In vivo epiluminescence microscopy: improvement of early diagnosis of melanoma. J Invest Dermatol 1993; 100:356S-362S.
25. Bauer J, Blum A, Strohhacker U, Garbe C. Surveillance of patients at high risk or cutaneous malignant melanoma using digital dermoscopy. Br J Dermatol 2005; 152:87-92.
26. Seidenari S, Pellacani G, Pepe P. Digital videomicroscopy improves diagnostic accuracy for melanoma. J Am Acad Dermatol 1998; 39:175-181.
27. Kittler H, Binder M. Risks and benefits of sequential imaging of melanocytic skin lesions in patients with multiple atypical nevi. Arch Dermatol 2001; 137:1590-1595.
28. Kittler H, Binder M. Follow-up of melanocytic skin lesions with digital dermoscopy: risks and benefits. Arch Dermatol 2002; 138:1379.
29. Schiffner R, Schiffner-Rohe J, Landthaler M, Stolz W. Long-term dermoscopic follow-up of melanocytic naevi: clinical outcome and patient compliance. Br J Dermatol 2003; 149:79-86.
30. Binder M, Kittler H, Seeber A, Steiner A, Pehamberger H, Wolff K. Epiluminescence microscopy-based classification of pigmented skin lesions using computerized image analysis and an artificial neural network. Melanoma Res 1998; 8:261-266.
31. Blum A, Luedtke H, Ellwanger U, Schwabe R, Rassner G, Garbe C. Digital image analysis for diagnosis of cutaneous melanoma. Development of a highly effective computer algorithm based on analysis of 837 melanocytic lesions. Br J Dermatol 2004; 151:1029-1038.
32. Rubegni P, Cevenini G, Burroni M, Dell'eva G, Sbano P, Cuccia A, Andreassi L. Digital dermoscopy analysis of atypical pigmented skin lesions: a stepwise logistic discriminant analysis approach. Skin Res Technol 2002; 8:276-281.
33. Kaufmann R. Surgical management of primary melanoma. Clin Exp Dermatol 2000; 25:476-481.
34. Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318:1159-1162.
35. Ringborg U, Andersson R, Eldh J, Glaumann B, Hafstrom L, Jacobsson S, et al. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer 1996; 77:1809-1814.
36. Thomas JM, Newton-Bishop J, A'Hern R, Coombes G, Timmons M, Evans J, et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004; 350:757-766.
37. Dummer R, Panizzon R, Bloch PH, Burg G. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2005; 210:39-44.
38. Hauschild A, Rosien F, Lischner S. Surgical standards in the primary care of melanoma patients. Onkologie 2003; 26:218-222.
39. Essner R. Surgical treatment of malignant melanoma. Surg Clin North Am 2003; 83:109-156.
40. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88:1484-1491.
41. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
42. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-399.
43. Ruiter DJ, Spatz A, van den Oord JJ, Cook MG. Pathologic staging of melanoma. Semin Oncol 2002; 29:370-381.
44. Thompson JF, McCarthy WH, Bosch CM, O'Brien CJ, Quinn MJ, Paramaesvaran S, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995; 5:255-260.
45. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355:1307-1317.
46. Li W, Stall A, Shivers SC, Lin J, Haddad F, Messina J, et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg 2000; 231:795-803.
47. Blaheta HJ, Ellwanger U, Schittek B, Sotlar K, MacZey E, Breuninger H, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 2000; 114:637-642.
48. Bieligk SC, Ghossein R, Bhattacharya S, Coit DG. Detection of tyrosinase mRNA by reverse transcription-polymerase chain reaction in melanoma sentinel nodes. Ann Surg Oncol 1999; 6:232-240.
49. Shivers SC, Wang X, Li W, Joseph E, Messina J, Glass LF, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998; 280:1410-1415.
50. Ulrich J, Bonnekoh B, Bockelmann R, Schon M, Schon MP, Steinke R, et al. Prognostic significance of detecting micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies: lessons from 322 consecutive melanoma patients. Eur J Cancer 2004; 40:2812-2819.
51. Gutzmer R, Kaspari M, Brodersen JP, Mommert S, Volker B, Kapp A, et al. Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies. Histopathology 2002; 41:510-518.
52. Mangas C, Hilari JM, Paradelo C, Rex J, Fernandez-Figueras MT, Fraile M, et al. Prognostic significance of molecular staging study of sentinel lymph nodes by reverse transcriptase-polymerase chain reaction for tyrosinase in melanoma patients. Ann Surg Oncol 2006; 13:910-918.
53. Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 2006; 24:2849-2857.
54. Buttner P, Garbe C, Bertz J, Burg G, d'Hoedt B, Drepper H, et al. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 1995; 75:2499-2506.
55. Eigentler TK, Buettner PG, Leiter U, Garbe C. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry. J Clin Oncol 2004; 22:4376-4383.
56. Garbe C, Ellwanger U, Tronnier M, Brocker EB, Orfanos CE. The New American Joint Committee on Cancer staging system for cutaneous melanoma: a critical analysis based on data of the German Central Malignant Melanoma Registry. Cancer 2002; 94:2305-2307.
57. Baughan CA, Hall VL, Leppard BJ, Perkins PJ. Follow-up in stage I cutaneous malignant melanoma: an audit. Clin Oncol (R Coll Radiol) 1993; 5:174-180.
58. Dicker TJ, Kavanagh GM, Herd RM, Ahmad T, McLaren KM, Chetty U, Hunter JA. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol 1999; 140:249-254.
59. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995; 274:1703-1705.
60. Garbe C, Paul A, Kohler-Späth H, Ellwanger U, Stroebel W, Schwarz M, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003; 21:520-529.
61. Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription- polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 2003; 97:1737-1745.
62. Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003; 290:3199-3206.
63. Muller-Horvat C, Radny P, Eigentler TK, Schafer J, Pfannenberg C, Horger M, et al. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. Eur J Cancer 2006; 42:342-350.
64. Belhocine TZ, Scott AM, Even-Sapir E, Urbain JL, Essner R. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 2006; 47:957-967.
65. Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006; 24:1178-1187.
66. Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982; 307:913-916.
67. Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106:1431-1442.
68. Mohr P, Weichenthal M, Hauschild A. Adjuvant therapy in melanoma. Onkologie 2003; 26:227-233.
69. Garbe C, Hauschild A, Linse R, Dummer R, Kapp A, Ulrich J, et al. Adjuvant treatment of patients with cutaneous melanoma and regional node metastasis with low dose interferon- or interferon- plus DTIC versus observation alone. Preliminary evaluation of a randomised multicenter DeCOG trial. 5th International Conference on the Adjuvant Therapy of Malignant Melanoma, Abstract booklet, No I-21, p. 14. 2004.
70. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17.
71. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18:2444-2458.
72. Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RMJ, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13:2776-2783.
73. Grob JJ, Dreno B, de la SP, Delaunay M, Cupissol D, Guillot B, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998; 351:1905-1910.
74. Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998; 16:1425-1429.
75. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001; 358:866-869.
76. Cameron DA, Cornbleet MC, MacKie RM, Hunter JA, Gore M, Hancock B, Smyth JF. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 2001; 84:1146-1149.
77. Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study - United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004; 22:53-61.
78. Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366:1189-1196.
79. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002; 20:1818-1825.
80. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003; 29:241-252.
81. Guerry D, Schuchter LM. Disseminated melanoma - is there a new standard therapy? N Engl J Med 1992; 327:560-561.
82. Schadendorf D. Is there a standard for the palliative treatment of melanoma? Onkologie 2002; 25:74-76.
83. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166.
84. Ringborg U, Rudenstam CM, Hansson J, Hafstrom L, Stenstam B, Strander H. Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study. Med Oncol Tumor Pharmacother 1989; 6:285-289.
85. Chiarion SV, Nortilli R, Aversa SM, Paccagnella A, Medici M, Corti L, et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res 2001; 11:189-196.
86. Young AM, Marsden J, Goodman A, Burton A, Dunn JA. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R Coll Radiol) 2001; 13:458-465.
87. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995; 13:910-913.
88. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990; 66:1873-1878.
89. Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 2003; 13:97-103.
90. Carmichael J, Atkinson RJ, Calman KC, MacKie RM, Naysmith AM, Smyth JF. A multicentre phase II trial of vindesine in malignant melanoma. Eur J Cancer Clin Oncol 1982; 18:1293-1295.
91. Nelimark RA, Peterson BA, Vosika GJ, Conroy JA. Vindesine for metastatic malignant melanoma. A phase II trial. Am J Clin Oncol 1983; 6:561-564.
92. Robinson WA, Mughal TI, Thomas MR, Johnson M, Spiegel RJ. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology 1986; 172:275-282.
93. Miller RL, Steis RG, Clark JW, Smith JW, Crum E, McKnight JE, et al. Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res 1989; 49:1871-1876.
94. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116.
95. Dorval T, Mathiot C, Chosidow O, Revuz J, Avril MF, Guillaume JC, et al. IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters. Biotechnol Ther 1992; 3:63-79.
96. Legha SS, Gianan MA, Plager C, Eton OE, Papadopoulous NE. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 1996; 77:89-96.
97. Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, et al. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 2001; 84:1036-1042.
98. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003; 4:748-759.